澳大利亚和新西兰的药物依赖性与开氯胺酮治疗耐药性抑郁症。

IF 4 2区 医学 Q1 PSYCHIATRY
Alistair Carroll, Adam Bayes, Mark Montebello, Jonathan Brett, Shalini Arunogiri, John B Saunders, Colleen K Loo
{"title":"澳大利亚和新西兰的药物依赖性与开氯胺酮治疗耐药性抑郁症。","authors":"Alistair Carroll, Adam Bayes, Mark Montebello, Jonathan Brett, Shalini Arunogiri, John B Saunders, Colleen K Loo","doi":"10.1177/00048674241242315","DOIUrl":null,"url":null,"abstract":"<p><p>Ketamine is a restricted and regulated medication in Australia and New Zealand, which has implications when considering treatment for patients with treatment-resistant depression and a history of illicit drug use, abuse or dependence. Regulations governing prescription of ketamine for treatment-resistant depression vary between jurisdictions in Australia and New Zealand, though most restrict use in those with drug dependence. There is substantial variation in definitions of drug dependence used in each jurisdiction, and between the legal and clinical definitions, with the latter specified in the current International Classification of Diseases, Eleventh Revision and <i>Diagnostic and Statistical Manual of Mental Disorders</i>, Fifth Edition. This paper reviews the literature assessing the risk of ketamine misuse and dependence in patients with a history of illicit drug use, abuse or dependence and presents recommendations for psychiatrists who prescribe ketamine in such patients with treatment-resistant depression.</p>","PeriodicalId":8589,"journal":{"name":"Australian and New Zealand Journal of Psychiatry","volume":" ","pages":"831-838"},"PeriodicalIF":4.0000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand.\",\"authors\":\"Alistair Carroll, Adam Bayes, Mark Montebello, Jonathan Brett, Shalini Arunogiri, John B Saunders, Colleen K Loo\",\"doi\":\"10.1177/00048674241242315\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Ketamine is a restricted and regulated medication in Australia and New Zealand, which has implications when considering treatment for patients with treatment-resistant depression and a history of illicit drug use, abuse or dependence. Regulations governing prescription of ketamine for treatment-resistant depression vary between jurisdictions in Australia and New Zealand, though most restrict use in those with drug dependence. There is substantial variation in definitions of drug dependence used in each jurisdiction, and between the legal and clinical definitions, with the latter specified in the current International Classification of Diseases, Eleventh Revision and <i>Diagnostic and Statistical Manual of Mental Disorders</i>, Fifth Edition. This paper reviews the literature assessing the risk of ketamine misuse and dependence in patients with a history of illicit drug use, abuse or dependence and presents recommendations for psychiatrists who prescribe ketamine in such patients with treatment-resistant depression.</p>\",\"PeriodicalId\":8589,\"journal\":{\"name\":\"Australian and New Zealand Journal of Psychiatry\",\"volume\":\" \",\"pages\":\"831-838\"},\"PeriodicalIF\":4.0000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Australian and New Zealand Journal of Psychiatry\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/00048674241242315\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/4/1 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Australian and New Zealand Journal of Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00048674241242315","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/4/1 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

摘要

在澳大利亚和新西兰,氯胺酮是一种受限制和管制的药物,这对考虑治疗患有难治性抑郁症并有非法药物使用、滥用或依赖史的患者有一定影响。澳大利亚和新西兰各辖区对氯胺酮治疗耐药性抑郁症的处方管理规定各不相同,但大多数辖区都限制对药物依赖患者使用氯胺酮。各司法管辖区对药物依赖的定义以及法律定义和临床定义之间存在很大差异,后者在现行的《国际疾病分类》第十一次修订版和《精神疾病诊断与统计手册》第五版中均有明确规定。本文回顾了评估有非法药物使用、滥用或依赖史的患者误用和依赖氯胺酮风险的文献,并向为此类难治性抑郁症患者开具氯胺酮处方的精神科医生提出了建议。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Drug dependence and prescribing ketamine for treatment-resistant depression in Australia and New Zealand.

Ketamine is a restricted and regulated medication in Australia and New Zealand, which has implications when considering treatment for patients with treatment-resistant depression and a history of illicit drug use, abuse or dependence. Regulations governing prescription of ketamine for treatment-resistant depression vary between jurisdictions in Australia and New Zealand, though most restrict use in those with drug dependence. There is substantial variation in definitions of drug dependence used in each jurisdiction, and between the legal and clinical definitions, with the latter specified in the current International Classification of Diseases, Eleventh Revision and Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. This paper reviews the literature assessing the risk of ketamine misuse and dependence in patients with a history of illicit drug use, abuse or dependence and presents recommendations for psychiatrists who prescribe ketamine in such patients with treatment-resistant depression.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.00
自引率
2.20%
发文量
149
审稿时长
6-12 weeks
期刊介绍: Australian & New Zealand Journal of Psychiatry is the official Journal of The Royal Australian and New Zealand College of Psychiatrists (RANZCP). The Australian & New Zealand Journal of Psychiatry is a monthly journal publishing original articles which describe research or report opinions of interest to psychiatrists. These contributions may be presented as original research, reviews, perspectives, commentaries and letters to the editor. The Australian & New Zealand Journal of Psychiatry is the leading psychiatry journal of the Asia-Pacific region.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信